Speaker illustration

Professor Deepak Bhatt

Brigham and Women's Hospital, Boston (United States of America)

Member of:

European Society of Cardiology

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women’s Hospital. After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master in Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic, where he also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention.

Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy?

Event: ESC Congress 2021 - The Digital Experience

Topic: Peripheral Vascular and Cerebrovascular Disease

Session type: Great Debates

Thumbnail

Controversies in Antiplatelet Treatment: Is Short-Term Dual Antiplatelet Therapy Safe and Effective after PCI?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Pharmacotherapy

Session type: Debate Session

Thumbnail

Residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Cardiovascular drugs in acute coronary syndromes: when to start and when to stop

Event: ESC CONGRESS 2019

Topic: Pharmacology and Pharmacotherapy

Session type: Symposium

Thumbnail

Statistics and clinical trials: a guide for the aspiring cardiologist.

Event: ESC Congress 2018

Topic: Trial Design

Session type: Symposium

Thumbnail

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Event: ESC Congress 2018

Topic: Acute Coronary Syndromes

Session type: Satellite Symposium

Thumbnail

The great debate: thrombocardiology post COMPASS.

Event: ESC Congress 2018

Topic: Cardiovascular Pharmacotherapy

Session type: Debate Session

Thumbnail

Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?

Event: ESC Congress 2018

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

The state of the science of LDL-C lowering in patients with coronary atherosclerosis

Event: ESC CONGRESS 2016

Topic: Atherosclerosis

Session type: Satellite Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk